

asc  
0590  
H  
#3

I hereby certify that this correspondence and any other documents referred to as enclosed herein, are being deposited in an envelope with the U.S. Postal Service "Express Mail Post Office to Addressee" service, Label Number EL 889 535 346 US, under 37 CFR \$1.10 on the date below and addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.:

Date:

September 7, 2001

By:

Jennifer Mahoney  
PATENT

Packet No. 55600.8004.US00

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RE APPLICATION OF:

Sokawa and Liu

SERIAL No.: 09/910,406

FILED: July 19, 2001

FOR: **COMPOSITION FOR TREATMENT OF AND  
METHOD OF MONITORING HEPATITIS C  
VIRUS USING INTERFERON-TAU**

EXAMINER: Unknown

ART UNIT: Unknown

**Information Disclosure Statement Within Three Months of  
Application Filing or Before First Action - 37 CFR 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

1. Timing of Submission

This information disclosure is being filed within three months of the filing date of this application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever occurs last [37 CFR 1.97(b)]. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

☒ Copies of the following references are enclosed:

- ☒ All cited references
- ☐ References marked by asterisks
- ☐ The following:

- ☐ Copies of the following references can be found in parent application Ser. No.:
- ☐ All cited references
  - ☐ References marked by asterisks
  - ☐ The following:

3. Effect of Information Disclosure Statement (37 CFR 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

4. Fee Payment

No fees are believed due. However, should the Commissioner determine that fees are due in order for this Information Disclosure Statement to be considered, the Commissioner is hereby authorized to charge such fees to Deposit Account No. 50-0665.

Respectfully submitted,



Date: 9-7-01

Larry W. Thrower  
Registration No. 47,994

Correspondence Address:

Customer No. 22918